Abnova (Taiwan)TPE:4133 -0.72%75 Net Margin % is 12.57% as of Dec. 2025, which is 13% above its 10-year median of 11.13. GuruFocus rates TPE:4133 with a GF Score™ of 75/100 and a GF Value™ of NT$28.30 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 946 Biotechnology companies, Abnova (Taiwan) ranks better than 71.04% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Abnova (Taiwan)'s Net Income for the
three
months ended in Dec. 2025 was NT$10.5 Mil. Abnova (Taiwan)'s Revenue for the
three
months ended in Dec. 2025 was NT$83.9 Mil. Therefore, Abnova (Taiwan)'s net margin for the quarter that ended in Dec. 2025 was 12.57%.
The historical rank and industry rank for Abnova (Taiwan)'s Net Margin % or its related term are showing as below:
TPE:4133'
s Net Margin % Range Over the Past 10 Years
Min: -0.33 Med: 11.13 Max: 18.18
Current: -0.33
TPE:4133's Net Margin % is ranked better than 71.04% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs TPE:4133: -0.33
Abnova (Taiwan) (TPE:4133) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Abnova (Taiwan) Net Margin % Related Terms
Abnova (Taiwan) Net Margin % Historical Data
* Premium members only.
The historical data trend for Abnova (Taiwan)'s Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4133 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Abnova (Taiwan)'s Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abnova (Taiwan) Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abnova (Taiwan)'s Net Margin % distribution charts can be found below:
* The bar in red indicates where Abnova (Taiwan)'s Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abnova (Taiwan) (TPE:4133) has a Net Margin % of 12.57% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Abnova (Taiwan) and its competitors. This is 13% above median its historical median of 11.13. According to the industry distribution chart, Abnova (Taiwan) ranks #274 out of 946 companies in the Biotechnology industry, placing it in the top 29%.
Is Abnova (Taiwan)'s Net Margin % too high?
Abnova (Taiwan)'s current Net Margin % of 12.57% is 13% above median its 10-year median of 11.13. Based on the distribution chart, Abnova (Taiwan) ranks #274 out of 946 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Abnova (Taiwan) has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abnova (Taiwan)'s Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abnova (Taiwan) ranks #274 out of 946 companies for Net Margin %. This puts Abnova (Taiwan) in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Abnova (Taiwan) and its competitors. Abnova (Taiwan)'s current Net Margin % is 12.57%, which is 13% above median its own 10-year median of 11.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abnova (Taiwan) stock overvalued right now?
Based on GuruFocus' analysis, Abnova (Taiwan) (TPE:4133) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$28.30, compared to a current price of NT$20.55 — trading 27.4% below its estimated fair value. The current Net Margin % is 12.57%, which is 13% above median its 10-year median of 11.13. Abnova (Taiwan)'s overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Abnova (Taiwan) (TPE:4133), the current Net Margin % is 12.57% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abnova (Taiwan) (TPE:4133) Overvalued in 2026?
Based on GuruFocus' analysis, Abnova (Taiwan) stock appears to be undervalued.
The current stock price of NT$20.55 is trading 27.4% below its estimated GF Value™ of NT$28.30.
GuruFocus considers Abnova (Taiwan) to be Modestly Undervalued.
Key valuation signals for TPE:4133:
Net Margin %: 12.57% (13% above median its 10-year median of 11.13)
GF Value™: NT$28.30 vs. price of NT$20.55 (27.4% below fair value)
No single metric tells the full story. See the TPE:4133 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abnova (Taiwan) Corp is engaged in developing, manufacturing, and selling monoclonal antibody, polyclonal antibody, proteins, medical inspection instruments and testing reagents, which are mainly antibody reagents, antibody chips or related products provided to and used by academic, research institutions or pharmaceutical factories. Geographically, it operates in America, Europe, Taiwan and Other Countries. It generates maximum revenue from America. Its products include: SARS-CoV/CoV-2, DNA, RNA new, Proteins/peptides, MaxPab, DNAxPab, Polyclonal Ab, Monoclonal Ab and Others. The company's services are: Gene synthesis & cytogenetics, Peptide services, Protein expression, Humanized antibody, Assay development, Conjugation, FFPE tumor tissue DNA, In situ hybridization (ISH) and Others.
75GF Score
Get the complete analysis for TPE:4133
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4133 has been successfully added to your 
